BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces that its 2026 half-year financial report has been made available to the public and filed with the French Financial Markets Authority (Autorité des marchés financiers). It can be consulted on the Company’s website, www.aelisfarma.c